Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of lumasiran in infants and young children with primary hyperoxaluria type 1
MOH_2019-03-03_006004Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Change in urinary oxalate excretion. Started Feb 2019; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on MOH_2019-03-03_006004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-03_006004.